Richard Glaze sold $17k of CNMD
Chief Information Officer at CONMED Corp. 257 shares at an average of $65.35, traded Feb 11, 2025, filed Feb 13, 2025.
Score components
- +15RoleOfficer
- 0Trade size$17k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-004596, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 11, 2025 | SOpen-market sale Common Stock | -257 | $65.35 | $17k | 0 | Feb 13, 2025 |
Related signals
Other insiders at CONMED Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | CONMED Corp | Richard Glaze Chief Information Officer | $11k 257 shares | -100% | |
| 33Weak | CONMED Corp | Todd W Garner Executive Vice President & CFO | $151k 3,500 shares | -66% | |
| 30Weak | CNMDsell CONMED Corp | Charles Farkas director | $107k 2,000 shares | -12% | |
| 47Moderate | CNMDsell CONMED Corp | Todd W Garner Executive Vice President & CFO | $31k 598 shares | -100% | |
| 33Weak | CNMDsell CONMED Corp | Charles Farkas director | $228k 4,000 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.